Last reviewed · How we verify

Intra-articular platelet-rich plasma

King Hamad University Hospital, Bahrain · FDA-approved active Small molecule Quality 5/100

Intra-articular platelet-rich plasma is a Small molecule drug developed by King Hamad University Hospital, Bahrain. It is currently FDA-approved. Also known as: Prp.

At a glance

Generic nameIntra-articular platelet-rich plasma
Also known asPrp
SponsorKing Hamad University Hospital, Bahrain
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Intra-articular platelet-rich plasma

What is Intra-articular platelet-rich plasma?

Intra-articular platelet-rich plasma is a Small molecule drug developed by King Hamad University Hospital, Bahrain.

Who makes Intra-articular platelet-rich plasma?

Intra-articular platelet-rich plasma is developed and marketed by King Hamad University Hospital, Bahrain (see full King Hamad University Hospital, Bahrain pipeline at /company/king-hamad-university-hospital-bahrain).

Is Intra-articular platelet-rich plasma also known as anything else?

Intra-articular platelet-rich plasma is also known as Prp.

What development phase is Intra-articular platelet-rich plasma in?

Intra-articular platelet-rich plasma is FDA-approved (marketed).

Related